Continuing on from the previous article.
Across the series of articles I have researched and written up, we have explored a central policy tension: how to balance access to effective medicines with the prevention of misuse and diversion.
Pseudoephedrine (PSE) sits directly at this intersection.
Pseudoephedrine remains one of the most effective oral nasal decongestants available, with controlled clinical trials demonstrating reductions in nasal airway resistance and improvements in congestion symptoms compared with placebo [1, 2].
However, PSE can also be diverted for illicit methamphetamine production, which prompted regulatory restrictions in Australia and internationally during the early 2000s [3].
The policy environment has since evolved.
Modern pharmacy practice now includes real-time monitoring systems, electronic purchase recording, and pharmacist-led screening processes that did not exist when many of these restrictions were first implemented [4, 5].
At the same time, a major shift occurred in the scientific evidence surrounding the substitute medicine used in many OTC products.
In 2023 the U.S. Food and Drug Administration advisory committee concluded that oral phenylephrine is ineffective for nasal congestion at approved doses [6].
This finding reinforced decades of pharmacological research showing that phenylephrine has limited oral bioavailability and therefore limited therapeutic benefit for nasal congestion.
Taken together, these developments raise a legitimate question for Australian policymakers:
Should the regulatory approach to effective nasal decongestants be reassessed in light of new scientific and monitoring evidence?
1) The regulatory framework already supports reassessment
Australia’s medicines scheduling system is governed by the Poisons Standard (SUSMP) and the Scheduling Policy Framework for Medicines and Chemicals, which guide how substances are classified and how they may be supplied [7, 8].
When determining scheduling decisions, regulators must consider multiple factors including:
- Toxicity and safety profile
- Therapeutic benefit and purpose of use
- Potential for abuse or misuse
- Public-health implications
- Available regulatory controls [8]
Importantly, the framework explicitly recognises that scheduling decisions should evolve when new evidence emerges or when improved regulatory controls become available [8].
Pseudoephedrine restrictions were introduced at a time when diversion monitoring systems were limited.
Today, however, pharmacy-based monitoring systems such as Project STOP allow pharmacists to track pseudoephedrine sales across pharmacies in real time [5].
This represents a substantial change in regulatory capability.
2) The therapeutic gap created by phenylephrine substitution
The replacement of pseudoephedrine with phenylephrine in many over-the-counter products created an unintended consequence: many patients are now relying on medicines with weak or absent evidence of clinical effectiveness.
Multiple pharmacological studies have demonstrated that pseudoephedrine produces measurable improvements in nasal airflow and congestion symptoms [1, 2].
In contrast, systematic reviews of oral phenylephrine have repeatedly found that the medicine performs no better than placebo in relieving congestion symptoms at standard doses [9].
These findings culminated in the 2023 FDA advisory committee decision that the scientific evidence does not support the effectiveness of oral phenylephrine as a nasal decongestant [6].
From a public-health perspective, ineffective treatments can produce several downstream effects, including:
- Repeated pharmacy visits
- Increased GP consultations
- Polypharmacy and self-medication stacking
- Patient dissatisfaction with OTC treatment
The therapeutic gap therefore has broader implications for healthcare utilisation and patient outcomes.
3) International regulatory signals
Global regulatory decisions often inform domestic policy discussions.
The FDA review of phenylephrine involved extensive evaluation of:
- Pharmacokinetic data
- Pharmacodynamic modelling
- Randomised clinical trials
- Real-world effectiveness evidence
The conclusion was clear: oral phenylephrine lacks meaningful clinical efficacy [6, 9].
Although Australian regulators operate independently, international regulatory developments frequently provide important signals for reassessment, particularly when they are based on large bodies of scientific evidence.
4) Pharmacist-led supply as the cornerstone of reform
Any realistic reform proposal must maintain safeguards against diversion while restoring access to effective therapy.
A pharmacist-led supply model offers a practical solution.
Under such a model pharmacists would be responsible for:
- Assessing patient symptoms
- Screening for contraindications
- Reviewing purchase history
- Recording supply through monitoring systems
Research evaluating the Australian Project STOP monitoring program has shown that pharmacy-based monitoring can significantly assist pharmacists in identifying suspicious purchase patterns and preventing diversion of pseudoephedrine products [5].
Evidence also suggests that monitoring programs are most effective when their use is mandatory and integrated into pharmacy practice systems [10].
In this context pharmacists act not merely as retailers, but as clinical gatekeepers and diversion-prevention partners.
5) A phased reform pathway
Policy reform rarely occurs through immediate systemic change. Instead, regulatory adjustments are typically introduced through staged evaluation.
A potential roadmap for reassessing pseudoephedrine access could involve several phases.
Phase 1: Evidence review
Regulators could initiate a comprehensive review of:
- Comparative efficacy of pseudoephedrine and phenylephrine
- Current diversion risks
- Effectiveness of monitoring systems
Phase 2: Stakeholder consultation
Consultation with key groups would ensure balanced policy development:
- Pharmacists
- Clinicians
- Addiction specialists
- Public-health experts
- Law-enforcement agencies
Phase 3: Risk-management design
If reform is considered appropriate, safeguards could include:
- Pharmacist-only supply
- Mandatory electronic monitoring
- Pack-size limits
- Identification requirements
Phase 4: Pilot implementation
Selected jurisdictions could test revised supply models while monitoring diversion rates and patient outcomes.
Phase 5: Ongoing evaluation
Continuous monitoring would allow regulators to refine policy if unintended consequences arise.
6) Aligning reform with broader healthcare priorities
Australia’s healthcare system is increasingly focused on expanding the clinical role of pharmacists in primary care.
Pharmacists already provide services such as:
- Vaccination
- Medication reviews
- Chronic disease management support
- Minor illness consultations
Allowing pharmacists to manage access to effective decongestants aligns with this broader healthcare direction.
It reinforces the role of pharmacists as accessible medicines experts embedded within the primary-care system.
Conclusion: evidence-based regulation must evolve
Pseudoephedrine presents a classic regulatory challenge: a medicine with clear therapeutic value but legitimate misuse risks.
The environment that originally drove restrictive policies has changed. Modern pharmacy monitoring systems, improved professional oversight, and new scientific evidence all contribute to a different policy landscape.
Reassessing pseudoephedrine access does not mean abandoning caution. It means recognising that evidence-based regulation should evolve alongside science, technology, and healthcare practice.
Ultimately, medicines policy should pursue a simple goal:
“Ensuring that patients have safe access to treatments that actually work”
References
[6] FDA clarifies results of recent advisory committee meeting on oral phenylephrine
[7] Scheduling basics of medicines and chemicals in Australia
[8] Scheduling Policy Framework for Medicines and Chemicals
Authors Note: Wilson Prasad also known as user name muefatiaki1966 is trying to leverage his experience working on products containing PSE in Australia for over 20 years and would like to express his interest and concern of PSE based products in Australia.
DeepDivers 
Leave a comment